GOLM1 and metabolic dysfunction-associated steatohepatitis: In terms of the clinical application of markers for MASH or liver fibrosis, GP73 measurements are not widely promoted, probably due to inadequate knowledge about (a) the pathophysiological mechanism underlying the interaction between GP73 and the inflammatory pathway, and (b) the diagnostic accuracy of GP73 in MASLD patients.